FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074199421> ?p ?o ?g. }

• W2074199421 endingPage "1143" @default.
• W2074199421 startingPage "1132" @default.
• W2074199421 abstract "Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to inhibit the growth of oestrogen positive breast cancer. However, triple-negative (TN) breast cancer is resistant to rapamycin treatment in vitro. We set to test a combination treatment of rapamycin with DNA-damage agent, cyclophosphamide, in a TN breast cancer model. By binding to and disrupting cellular DNA, cyclophosphamide kills cells via interfering with their normal functions. We assessed the responses of nude mice bearing tumour xenografts of TN MDA-MB-231 cells to the combination of rapamycin and cyclophosphamide in both orthotopic mammary and lung-metastasis models. We tracked tumour growth and metastasis by bioluminescent imaging and examined the expression of Ki67, CD34 and HIF-1alpha in tumour tissues by immunohistochemistry and apoptosis index with TUNEL assay, and found that MDA-MB-231 cells are sensitive to rapamycin therapy in orthotopic mammary, but not in lung with metastasis. Rapamycin when combined with cyclophosphamide is found to have a more significant effect in reducing tumour volume and metastasis with a much improved survival rate. Our data also show that the sensitivity of TN tumours to rapamycin is associated with the microenvironment of the tumour cells. The data indicate that in a relatively hypoxic environment HIF-1alpha may play a role in mediating the anti-cancer effect of rapamycin and cyclophosphamide may prevent the feedback activation of Akt by rapamycin. Overall our results show that rapamycin plus cyclophosphamide can achieve an improved efficacy in suppressing tumour growth and metastasis, suggesting that the combination therapy can be a promising treatment option for TN cancer." @default.
• W2074199421 created "2016-06-24" @default.
• W2074199421 creator A5008607043 @default.
• W2074199421 creator A5015077092 @default.
• W2074199421 creator A5034804463 @default.
• W2074199421 creator A5044275686 @default.
• W2074199421 creator A5048001261 @default.
• W2074199421 creator A5054283476 @default.
• W2074199421 creator A5054513872 @default.
• W2074199421 creator A5060039147 @default.
• W2074199421 creator A5063863193 @default.
• W2074199421 creator A5066004193 @default.
• W2074199421 creator A5073577367 @default.
• W2074199421 creator A5080825168 @default.
• W2074199421 creator A5083108381 @default.
• W2074199421 date "2010-04-01" @default.
• W2074199421 modified "2023-10-12" @default.
• W2074199421 title "Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study" @default.
• W2074199421 cites W1511853133 @default.
• W2074199421 cites W1979861893 @default.
• W2074199421 cites W1988754609 @default.
• W2074199421 cites W1989663680 @default.
• W2074199421 cites W1991843895 @default.
• W2074199421 cites W2013084027 @default.
• W2074199421 cites W2014245338 @default.
• W2074199421 cites W2018022997 @default.
• W2074199421 cites W2020820485 @default.
• W2074199421 cites W2026569756 @default.
• W2074199421 cites W2027953312 @default.
• W2074199421 cites W2028704745 @default.
• W2074199421 cites W2029225165 @default.
• W2074199421 cites W2046445256 @default.
• W2074199421 cites W2051989799 @default.
• W2074199421 cites W2073097835 @default.
• W2074199421 cites W2075997152 @default.
• W2074199421 cites W2083466846 @default.
• W2074199421 cites W2091352369 @default.
• W2074199421 cites W2098176107 @default.
• W2074199421 cites W2110511425 @default.
• W2074199421 cites W2112001957 @default.
• W2074199421 cites W2116355318 @default.
• W2074199421 cites W2121117803 @default.
• W2074199421 cites W2134951683 @default.
• W2074199421 cites W2139552047 @default.
• W2074199421 cites W2145392262 @default.
• W2074199421 cites W2150609042 @default.
• W2074199421 cites W2168298851 @default.
• W2074199421 doi "https://doi.org/10.1016/j.ejca.2010.01.014" @default.
• W2074199421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20156674" @default.
• W2074199421 hasPublicationYear "2010" @default.
• W2074199421 type Work @default.
• W2074199421 sameAs 2074199421 @default.
• W2074199421 citedByCount "35" @default.
• W2074199421 countsByYear W20741994212012 @default.
• W2074199421 countsByYear W20741994212013 @default.
• W2074199421 countsByYear W20741994212014 @default.
• W2074199421 countsByYear W20741994212015 @default.
• W2074199421 countsByYear W20741994212016 @default.
• W2074199421 countsByYear W20741994212017 @default.
• W2074199421 countsByYear W20741994212018 @default.
• W2074199421 countsByYear W20741994212019 @default.
• W2074199421 countsByYear W20741994212021 @default.
• W2074199421 crossrefType "journal-article" @default.
• W2074199421 hasAuthorship W2074199421A5008607043 @default.
• W2074199421 hasAuthorship W2074199421A5015077092 @default.
• W2074199421 hasAuthorship W2074199421A5034804463 @default.
• W2074199421 hasAuthorship W2074199421A5044275686 @default.
• W2074199421 hasAuthorship W2074199421A5048001261 @default.
• W2074199421 hasAuthorship W2074199421A5054283476 @default.
• W2074199421 hasAuthorship W2074199421A5054513872 @default.
• W2074199421 hasAuthorship W2074199421A5060039147 @default.
• W2074199421 hasAuthorship W2074199421A5063863193 @default.
• W2074199421 hasAuthorship W2074199421A5066004193 @default.
• W2074199421 hasAuthorship W2074199421A5073577367 @default.
• W2074199421 hasAuthorship W2074199421A5080825168 @default.
• W2074199421 hasAuthorship W2074199421A5083108381 @default.
• W2074199421 hasConcept C111335760 @default.
• W2074199421 hasConcept C121608353 @default.
• W2074199421 hasConcept C126322002 @default.
• W2074199421 hasConcept C150903083 @default.
• W2074199421 hasConcept C161997846 @default.
• W2074199421 hasConcept C190283241 @default.
• W2074199421 hasConcept C207001950 @default.
• W2074199421 hasConcept C2776694085 @default.
• W2074199421 hasConcept C2776755627 @default.
• W2074199421 hasConcept C2777921159 @default.
• W2074199421 hasConcept C2779013556 @default.
• W2074199421 hasConcept C2780278673 @default.
• W2074199421 hasConcept C502942594 @default.
• W2074199421 hasConcept C530470458 @default.
• W2074199421 hasConcept C54009773 @default.
• W2074199421 hasConcept C54355233 @default.
• W2074199421 hasConcept C55493867 @default.
• W2074199421 hasConcept C71924100 @default.
• W2074199421 hasConcept C81885089 @default.
• W2074199421 hasConcept C86554907 @default.
• W2074199421 hasConcept C86803240 @default.
• W2074199421 hasConceptScore W2074199421C111335760 @default.

• next